Evidence map›Paper›PMID 35441358›Full record

ArticleLangenbeck's archives of surgery2022

Early Return to Intended Oncologic Therapy after implementation of an Enhanced Recovery After Surgery pathway for gastric cancer surgery.

Maria Garcia-Nebreda, Andrés Zorrilla-Vaca, Javier Ripollés-Melchor, Ane Abad-Motos, Edurne Alvaro Cifuentes, Alfredo Abad-Gurumeta, Gabriel E Mena, Michael C Grant, Gloria Paseiro-Crespo

Abstract read
PubMed Publisher
In one paragraph

Article in Langenbeck's archives of surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Impact of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel delivery on postoperative survival in locally advanced oesophagogastric adenocarcinoma.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maria Garcia-NebredaDepartment of Surgery, Infanta Leonor University Hospital, Madrid, Spain. nebreda_maria@hotmail.com.ORCID http://orcid.org/0000-0002-9118-9392
Andrés Zorrilla-VacaDepartment of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8140-8486
Javier Ripollés-MelchorGrupo Español de Rehabilitación Multimodal (GERM), Zaragoza, Spain.ORCID http://orcid.org/0000-0002-1958-9316
Ane Abad-MotosGrupo Español de Rehabilitación Multimodal (GERM), Zaragoza, Spain.ORCID http://orcid.org/0000-0002-9644-2887
Edurne Alvaro CifuentesDepartment of Surgery, Infanta Leonor University Hospital, Madrid, Spain.ORCID http://orcid.org/0000-0001-6793-3188
Alfredo Abad-GurumetaGrupo Español de Rehabilitación Multimodal (GERM), Zaragoza, Spain.ORCID http://orcid.org/0000-0003-3331-5589
Gabriel E MenaDepartment of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-2235-4892
Michael C GrantDepartment of Anesthesiology and Critical Care Medicine, The Johns Hopkins Hospital, Baltimore, MD, USA.
Gloria Paseiro-CrespoDepartment of Surgery, Infanta Leonor University Hospital, Madrid, Spain.ORCID http://orcid.org/0000-0003-2555-0212

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTime to initiation and completion of adjuvant therapy are critical to improve postoperative oncologic outcomes. This study aims to determine whether an Enhanced Recovery After Surgery (ERAS) pathway for gastric cancer surgery promotes early Return to Intended Oncologic Therapy (RIOT).

methodsThis is a before-after intervention study including patients with gastric adenocarcinoma who underwent surgery from January 2016 to January 2021. Two periods were denoted based upon the implementation date of our institutional ERAS pathway (June 2018). Our primary outcome was time to RIOT after surgery. Hodges-Lehmann analysis was used to estimate median differences of non-parametric outcomes.

resultsSeventy patients with gastric adenocarcinoma were included (35 in pre-ERAS period and 35 in post-ERAS period). Fourteen of the pre-ERAS and twenty-two patients of the post-ERAS period received adjuvant therapy. Time to RIOT was reduced in the post-ERAS period (median 39 days, IQR 31-49) by 12 days (95% CI 3-14 days, p = 0.01) compared to the pre-ERAS period (median 51 days, IQR 42-62). Length of hospital stay (LOS) was lower in the ERAS group (6 days, IQR 5-11 vs 10 days, IQR 8-13, p < 0.01).

conclusionOur institutional ERAS pathway for gastric cancer surgery was associated with earlier RIOT and shorter LOS.

Indexed as

AdenocarcinomaDigestive System Surgical ProceduresEnhanced Recovery After SurgeryStomach NeoplasmsHumansLength of StayPostoperative ComplicationsAdjuvant chemotherapyComplicationsGastrectomyPerioperative careSurgical oncologyTime-to-treatment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.